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Available online 16 April 2016Excess lipid storage is an epidemic problem in human populations. Thus, the identiﬁcation of small molecules to
treat or prevent lipid storage-related metabolic complications is of great interest. Here we screened N320.000
compounds for their ability to prevent a cellular lipid accumulation phenotype. We used ﬂy cells because the
multifarious tools available for this organism should facilitate unraveling the mechanism-of-action of active
small molecules. Of the several hundred lipid storage inhibitors identiﬁed in the primary screenwe concentrated
on three structurally diverse and potent compound classes active in cells of multiple species (including human)
and negligible cytotoxicity. Together with Drosophila in vivo epistasis experiments, RNA-Seq expression proﬁles
suggested that the target of one of the small molecules was diacylglycerol acyltransferase 1 (DGAT1), a key en-
zyme in the production of triacylglycerols and prominent human drug target. We conﬁrmed this prediction by
biochemical and enzymatic activity tests.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cells of organisms from all phyla balance ﬂuctuations in energy de-
mand and supply by the regulated deposition and remobilization of ener-
gy rich storage molecules. Among these, the neutral lipids are the most
efﬁcient. Neutral lipid synthesis relies on the conversion of surplus fatty
acids by multiple biochemical pathways into triacylglycerols (TAG) and
sterol esters (SE). TAG and SE are stored in specialized cellular organelles,
called lipid droplets (LDs) (Farese andWalther, 2009;Murphy, 2001). LDsvartis Institutes for Biomedical
y and Optimization, 5 Research
. This is an open access article underconsist of a hydrophobic core harboring the storage lipids surrounded by
a phospholipid monolayer and associated proteins. In addition to the en-
ergy buffering function, the conversion of fatty acids tomono-, di-, and ﬁ-
nally TAG protects cells from lipotoxicity. Additionally, lipids stored
within LDs also serve as anabolic buildingblocks formembrane, hormone,
and other synthesis processes. While themolecular details of the regulat-
ed lipid storage remobilization in adipocytes are emerging (Lass et al.,
2011), many details of cellular lipid metabolism remain elusive.
In healthy individuals, lipid storage amounts rely on the balance be-
tween energy intake and expenditure. However, modern lifestyles are
marked by the excessive intake of high caloric food and only limited
physical activity. Additionally, genotype, epigenetic effects and the gut
microbiome affect energy storage (Carone et al., 2010; Farooqi and
O'Rahilly, 2007; Lusis et al., 2008; Sullivan and Grove, 2009;
Turnbaugh et al., 2006). These intrinsic and extrinsic factors havethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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individuals, which has created a global epidemic. Aberrant lipid storage
amounts (high or low) are associated with or cause many other dis-
eases. For example, obesity co-morbidities include increased suscepti-
bility to diabetes, atherosclerosis, cancer, or infections (Gross and
Silver, 2014). In addition to obesity, ectopic lipid deposition of the
liver (liver steatosis), muscle or glia cells of individuals facing neurode-
generation (Liu et al., 2015; Shulman, 2014; Zámbó et al., 2013) as well
as the replication of certain pathogens including chlamydia or Hepatitis
C virus (Boulant et al., 2008; Kumar et al., 2006) depend on LDs. Thus,
there is great need for pharmacological approaches to understand and
treat a host of lipid storage phenotypes.
Phenotypic screening approaches are commonly used to identify
small molecules affecting processes where the molecular details are un-
known (Eder et al., 2014). In some cases, it is desirable to understand
the molecular mechanism-of-action of compounds derived from pheno-
typic screens butmapping the activity of compounds tomolecular targets
presents a signiﬁcant screening bottleneck. Different strategies have been
used for this difﬁcult task including complementary RNAi screening for
phenocopies (Gonsalves et al., 2011; Perrimon et al., 2007; Winter et al.,
2011) or biochemical target identiﬁcation strategies using afﬁnity enrich-
ment experiments coupled to themass spectrometry based identiﬁcation
of bound proteins (Vendrell-Navarro et al., 2015; Ziegler et al., 2013).
Here we used the non-mammalianmodel systemDrosophila to iden-
tify small molecule inhibitors of cellular lipid deposition by a phenotypic
high-throughput screen. The Drosophila genome harbors many of the
same genes regulating metabolism as humans (Baker and Thummel,
2007) and has developed into a vital tool in metabolic research
(Kühnlein, 2011; Pandey and Nichols, 2011; Rajan and Perrimon, 2011).
While there are obvious differences in the life histories of mammals and
ﬂies, as well as ﬂy-speciﬁc metabolic details such as sterol auxotrophy
(Carvalho et al., 2010) and the absence of an omega-3 and omega-5
fatty acid requirement (Shen et al., 2010) there are many more similari-
ties that make Drosophila an attractive model. For example, genes
encoding lipid metabolic enzymes and regulators (Buszczak et al., 2002;
Tian et al., 2011; Wilﬂing et al., 2013) as well as important hormones
such as insulin (Böhni et al., 1999), glucagon (Grönke et al., 2007), and
leptin (Rajan and Perrimon, 2012) are functionally conserved in the ﬂy.
It is increasingly clear that LD cell biology is essentially the same in ﬂies
and mammals, as for example homologous PERILIPIN proteins coat
(Beller et al., 2010; Grönke et al., 2003), and lipases dock (Bi et al.,
2012; Grönke et al., 2005), with LDs in both organisms.
To take full advantage of the unparalleled genetic tools available in
Drosophila to develop small molecules that inhibit lipid storage, we
used a tiered experimental approach that relied on a primary screen
in Drosophila cells, followed by the generation of derivatives of selected
top candidate structural scaffolds for testing in a range of mice, monkey,
and human cells. Those small molecules showing reduced lipid storage
in these cells were further analyzed by functional assays and RNA-Seq
based transcriptional proﬁling to determine what pathways were al-
tered. By this effort, we could map the activity of one group of small
molecules to the inhibition of the lipogenic diacylglycerol acyltransfer-
ase 1 (DGAT1) enzyme, which is a known human obesity drug target.
2. Materials & Methods
All methods are described in detail in the Supplemental Experimen-
tal Procedures section.
2.1. qHTS Screening and Chemical Syntheses of Small Molecule Derivatives,
Oleic Acid Feeding and Small Molecule Treatment of Cells
Drosophila and mammalian cells were kept in the appropriate medi-
um supplemented with 5% FCS and the indicated amount of small mole-
cule or DMSO solvent alone. For the quantitative high-throughput small
molecule screen (qHTS; PubChemAssay ID2685), S3 cellsweredispensedin 1536-well plates and treated with multiple concentrations of each li-
brary compound (46 μM to 3 nM in 1:5 dilution steps). LDs were induced
by the addition of 400 μM OA bound to fatty acid free BSA. After 18 h of
treatment, the cells were ﬁxed and stained for LDs with the hydrophobic
dye BODIPY 493/503 and the Cell Tracker Red CMTPXdye (both fromMo-
lecular Probes/Invitrogen) to enumerate cell number. Fluorescence was
detected by excitation of the ﬂuorophoreswith a 488 nm laser on an Acu-
men Explorer (TTP Lab Tech, Hertfordshire, UK) and quantiﬁcation of the
lipid storage levels was normalized to the cell number.
To test for defects in cholesteryl-ester LDdeposition in Drosophila S3
or murine AML12 cells, we added either NBD-cholesterol (Molecular
Probes/Invitrogen) alone or in combination with OA in the presence of
the indicated amounts of small molecule or the solvent DMSO alone. Ex-
periments were analyzed by ﬂuorescence microscopy.
In addition to BODIPY493/503 we also used the lipophilic dye HCS
LipidTOX deep red to stain LDs and counted cells based on DNA/nuclei
signals achieved by Hoechst or DAPI staining. Images were either qual-
itatively scored by visual inspection or lipid storage amounts were
quantiﬁed using custom CellProﬁler (Kamentsky et al., 2011) image
segmentation algorithms. As an alternative to image-based readouts,
lipids were extracted from the cells and analyzed by thin layer chroma-
tography or HPLC-ELSD.
2.2. Measurement of Fatty Acid Uptake
Drosophila S3 cells were incubated with the ﬂuorescent C12 fatty
acid tracer QBT ﬂuorescent fatty acid uptake reagent (Molecular De-
vices) according to the manufacturer's description. Cells were subse-
quently analyzed by confocal microscopy.
For the COS7 cell experiments, the cells received a short pulse of a
mixture of cold and 3H-labeled OA in the presence of the indicated
small molecule amount or the DMSO solvent alone. The cells were rap-
idlywashed and the internalized radioactivity was quantiﬁed by scintil-
lation counting.
2.3. Next Generation Sequencing Experiments Including Data Analysis
We treated 36 samples of Drosophila S3 cells with 1 μM of the re-
spective inactive or active compounds for four hours in serum-
reduced medium including 5% FCS. Multiple controls for the effect of
OA and DMSO were included. Each sample was measured at least in
triplicate. Following treatment, the total RNA was extracted from the
cells and processed for RNA-Seq experiments. Details concerning the
treatment of the cells, library preparation, sequencing, data analysis
and quality control measures are described in depth in the Supplemen-
tal Experimental Procedures and in GEO accession GSE67503.
2.4. Fatty Acid Beta-oxidation Measurements
Fatty acid β-oxidationwasmeasured as previously described (Wang
et al., 2009, 2011) using metabolic radioactive labeling of murine
AML12 cells grown in the presence of DMSO solvent only or the indicat-
ed small molecule. Both CO2 production and the amount of acid soluble
metabolites (ASM) were quantiﬁed.
2.5. Drosophila Experiments
Drosophila were kept on a standard cornmeal/molasses diet for prop-
agation. For compound treatment experiments we included 10 to 20 μM
of the small molecule or the DMSO solvent only (ﬁnal concentration
0.2% DMSO) in food which consisted of: 0.624 g Agar, 8 g polenta, 1 g
soy ﬂour, 1.8 g dry yeast, 2.2 g treacle, 8 gmalt extract and 1.5mL nipagin
solution (10% in Ethanol) and 0.63 mL propionic acid per 100 mL. Food
was cooled to approximately 60 °C before we added the compound
and/or DMSO andwas aliquoted to the ﬂy vials where it solidiﬁed. Paren-
tal ﬂies were placed on this food and allowed to lay eggs for three days
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completed theirwhole development in the presence of compound and/or
DMSO.We collected larvae, freshly eclosed ﬂies, and six day post eclosion
adults and measured their triglyceride content using established proto-
cols (Hildebrandt et al., 2011). High-fat diet treatment was done by the
addition of 10% coconut oil (Sigma-Aldrich) to the food and followed
established protocols (Shirazi et al., 2014). Details of the ﬂy experiments
aswell as information concerning the differentﬂy strains used are provid-
ed in the Supplemental Experimental Procedures section.
3. Results
3.1. A Phenotypic, Quantitative High-throughput Screen Identiﬁes Potent
Inhibitors of Lipid Deposition
To identify small molecules reducing cellular lipid storage amounts
we used a quantitative-high throughput image-based assay to measureFig. 1.qHTS screen identiﬁes potent lipid storage inhibitors. (a) Summary of the qHTS screening
S3 cells incubated with 400 μM OA. All structures were tested in six different concentrations a
presence or absence of the characteristics of a classical sigmoidal dose-response curve, activ
described in: (Inglese et al., 2006)). Only high-quality inhibitors showing a CC 1 (perfect sigm
the following. The bar plot provides information concerning the number of high- and low qua
as curve class 1.1 (cc-1.1), 1682 compounds belonged to cc-1.2 (203 high-quality and 1479
classiﬁed as cc-2.2 (1341 high-quality and 2147 low-quality hits), and 5532 low-quality in
scaffolds (“chemotypes”; CT) represented by structures 1 to 3, which resulted in low lipid sto
(CT2; TPE) or arylureido (CT3; AU) core. The pie charts depict that the structures showed
phenotype. The synthesis of analogs in the course of structure–activity relationship (SAR) st
based on the structure core abbreviation followed by a unique number separated by a dash
reduction of cellular lipid storage levels and affected viability only at extremely high concent
error of the mean (SEM); n = 2 wells). (d) Drosophila S3 cells incubated with 600 μM OA a
Also see Figure S1. Scale bars in panel (d) represent 50 μm.LDnumber per cell in the presence of excess free fatty acid inDrosophila
cells. In the absence of exogenous free fatty acids, the embryonic Dro-
sophila Kc167 and S3 cell lines store little lipid. However, when we
added free fatty acids in the form of oleic acid (OA) to the media, both
cell lines accumulated LDs within 16 h (Figure S1a–c). As S3 cells
showed higher lipid storage capacity, and thus an elevated dynamic
range and more robust response, we used these cells for the screening
campaign.
Following exploratory screens with the Library of Pharmacologi-
cally Active Compounds (LOPAC; Sigma-Aldrich), Tocris (Tocris Bio-
science), and the National Institutes of Health (NIH) Chemical
Genomics Center (NCGC) Pharmaceutical Collection (Huang et al.,
2011) (data not shown), we screened 320,864 small molecules
from the Molecular Libraries Small Molecule Repository in six con-
centrations spanning four orders of magnitude (Pubchem Bioassay
ID 2685). In total, we identiﬁed 2623 high-quality lipid storage in-
hibitors that showed a strong quantitative effect on LDs (Fig. 1a).results. TheMLSMR compound librarywas tested for lipid storage inhibitors onDrosophila
nd dose-response activity relationships were calculated for each compound. Based on the
ities were classiﬁed (compare to qHTS introduction and curve class (CC) classiﬁcation
oidal shape) or CC 2 (sigmoidal shape lacking one of the asymptotes) were considered in
lity inhibitors broken down to compound curve classes. 248 compounds were classiﬁed
low-quality hits), cc-2.1 contained 831 high-quality inhibitors, 3488 compounds were
hibitors belonged to cc-3. (b) We concentrate on three structurally diverse chemical
rage. The structures are characterized by a tetrahydroindazole (CT1; THI), thienopyrrole
no activity in most other MLSMR screens, suggesting speciﬁcity for the lipid storage
udies resulted in highly active structures (structures 4 to 6). Derivative nomenclature is
(compare with Figure S2). (c) The optimized structures resulted in a dosage-dependent
rations (CT1 = THI-4; CT2 = TPE-5 and CT3 = AU-6; data is given as mean ± standard
nd the indicated concentrations of CT1 (THI-4), CT2 (TPE-5) and CT3 (AU-6) overnight.
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tion of ﬁltering criteria including efﬁcacy, concentration dependency
(curve class), low cytotoxicity, and the presence of multiple structur-
ally similar compounds. This procedure followed the “Quantitative
high-throughput screening (qHTS) strategy” (Inglese et al., 2006).
In addition to the 2623 high-quality lipid storage inhibitors, we
also identiﬁed 223 high-quality lipid storage activators. Finally, we
identiﬁed 9158 inhibitors and 5880 activators with low quality
(Fig. 1a).
We concentrated on three unique chemical scaffolds, or
chemotypes (CT), based on tetrahydroindazole (CT1; THI),
thienopyrrole (CT2; TPE) or arylureido (CT3; AU) cores. These
small molecules were not frequent hits in previous Molecular Librar-
ies Program screens (Fig. 1b), suggesting a potential for speciﬁcity. In
order to guide the development of more potent CT derivatives, we
undertook a medicinal chemistry effort to better understand struc-
ture activity relationships (SAR). In total, we synthesized 89 struc-
tural variants (Figure S2) and obtained potent and non-toxic
modulators of lipid stores with EC50 values in the pM–nM range
(Fig. 1b–d and Figure S1d–f). In comparison to the known acyl-CoA
synthase inhibitor TriacsinC (Igal et al., 1997), which we used as a
positive control, two of the three CTs showed a superior efﬁcacy
with half maximal effective concentrations (EC50) of 90 nM for
TriacsinC and 0.34 and 9 nM for CT1 and CT2, respectively (Fig. 1b,c).
3.2. The activity of the Identiﬁed Lipid Storage Inhibitors is Evolutionary
Conserved
To be an effective tool or lead compound for drug development, it
was important that these analogs were potent modulators of lipid stor-
age in mammalian cells. We chose monkey COS7 kidney and mouse
AML12 hepatocytes to test all 89 generated derivatives (Fig. 2 and
Figure S2). In the presence of OA, 12–19% of the derivatives of each CT
showed activity in both mammalian and ﬂy cell lines (Fig. 2 and
Figure S2). Additionally, we identiﬁed small molecules with species-
speciﬁc activities as well as analogs with low activities across all cell
types. These data suggest that a SAR approach maximizes conserved
phenotypic responses to CTs.
3.3. Expression Proﬁling Guides Chemotype Classiﬁcation
Cells showprominent transcriptional changes as a result ofmetabol-
ic changes in nutrient availability or stress (Choi et al., 2012; DeGottardi
et al., 2007; De Nadal et al., 2011). We hypothesized that changes in
gene expression signatures could focus our attention on speciﬁc path-
ways as well as guide classiﬁcation of CT effects on metabolism. CTs
with a similar mechanism-of-action should share gene expression sig-
nature aspects. We therefore performed RNA-Seq experiments on S3
cells after 4 h of treatment (Fig. 3a,b and Figures S3 & S4; for details
see Supplemental Methods Section, Supplemental Tables S1–S3 in the
online version at http://dx.doi.org/10.1016/j.ebiom.2016.04.014.) to de-
termine if the three CTs had a similar effect on gene expression, or
whether there were expression signatures consistent with distinct
mechanisms of action.
In addition to active CT derivatives we also included derivatives
showing no or only little activity. This way we could identify CT-
speciﬁc gene expression changes unrelated to the lipid storage pheno-
type and thus representing a more general response to the CT structure
as well as potential off-target effects. When we quantiﬁed the number
of differentially expressed genes between the DMSO treated control
and active or inactive CT derivatives (Figure S4a; p-value b 0.001) re-
spectively, treatment with the active small molecule derivatives result-
ed in many more differentially expressed genes as compared to the
controls. Thus, gene expression proﬁling appears to be diagnostic for
the compound-induced lipid storage phenotype.When we clustered the expression measures of genes that were
differentially expressed between at least two treatments, we obtain-
ed ﬁve clusters (Fig. 3a, Figure S4; Table S4 in the online version at
http://dx.doi.org/10.1016/j.ebiom.2016.04.014.). In OA-fed control
cells, expression of cluster 1 genes was lower than in cells without
exogenous free fatty acids. Cluster 1 was enriched in genes encoding
enzymes that synthesize lipids and phospholipids based on Gene On-
tology (GO) analysis (Fig. 3b, Figure S4d, Tables S4 & S5 in the online
version at http://dx.doi.org/10.1016/j.ebiom.2016.04.014.), consis-
tent with down-regulation of fatty acid synthesis in the presence of
an exogenous supply. Clusters 2 and 3 were similarly expressed in
non-compound-treated control cells with or without OA and showed
no obvious link to lipid metabolism based on GO term analysis. These
genes showed reduced expression in cells treated with CT1 or CT3,
raising the possibility of a more general cellular response or off-
target effects. Cluster 4 genes were upregulated by OA addition and
enriched for genes encoding regulatory functions during differentia-
tion (Figure S4d). These genes showed modestly decreased expres-
sion following treatment with CT3. Cluster 5 was highly enriched in
genes that encode proteins involved in shunting lipids to other path-
ways, such as the TCA cycle, alpha- and beta-oxidation (Figure S4d)
and was upregulated following treatment with all three CTs. This
suggests that the cellular phenotype of reduced lipid storage was
achieved not by blocking fatty acid transport into cells, but by en-
hanced catabolism. To test the immediate effect of compound activ-
ity on the fatty acid uptake (e.g. by competitive effects during the
fatty acid transport), we performed radiolabeled fatty acid uptake
experiments (Fig. 3c). Here, we noted no signiﬁcant difference as
compared to control cells. When we provided ﬂuorescently labeled
fatty acids to DMSO treated control cells (Fig. 3d) they were success-
fully incorporated in LDs. Cells which received on top of the ﬂuores-
cent fatty acids unlabeled oleic acid showed more prominent lipid
stores (middle picture in Fig. 3d). CT2 treated cells also incorporated
the ﬂuorescently labeled fatty acids in LDs (Fig. 3d). However, the
total ﬂuorescence intensity was lower as compared to the DMSO
treated control cells, probably because of the reduced lipid storage
phenotype. These data indicate that CT treatment indeed has little
to no impact on the internalization of fatty acids. Thus, to achieve
the low lipid storage phenotype, fatty acids must be shunted into
other pathways to convert excess free fatty acids to energy produc-
tion, possibly to protect from lipotoxicity.
While we observed a core set of changes consistent with rerouting
lipids to energy production, there were also CT speciﬁc changes in ex-
pression (Fig. 3, Figure S4e). CT1 treated cells showed increased expres-
sion of genes encoding both anabolic and catabolic lipid metabolism
functions (Fig. 3a,b). These changes in gene expression are consistent
with a simultaneous increase in lipid synthesis (e.g. the fatty acid syn-
thase CG3523; (Pierre et al., 2014)), and increased lipolysis (e.g.
brummer lipase; (Grönke et al., 2005)) from LDs (compare Table S1 in
the online version at http://dx.doi.org/10.1016/j.ebiom.2016.04.014.).
This suggests a futile cycle of lipid synthesis andbreakdown. CT2 treated
cells showed more restricted changes in gene expression among genes
that also respond to OA loading (clusters 2–4; Fig. 3a), suggesting a
role in blocking lipid production. CT3 resulted in upregulated expres-
sion of genes involved in the xenobiotic response such as Glutathione-
S-transferases (mgstl, Gst T1, Gst T2, Gst T3 and GstE2) or ATP-
coupled export proteins (CG2316) that may result in biological clear-
ance (Table S1 in the online version at http://dx.doi.org/10.1016/j.
ebiom.2016.04.014.), in addition to reduced expression of genes in clus-
ters 2–4.
The limited number of CT2 speciﬁc gene expression changes (23
genes were differentially regulated; other changes can be explained
by the addition of OA; please compare Table S3 in the online version
at http://dx.doi.org/10.1016/j.ebiom.2016.04.014.) were in agreement
with a limited and speciﬁc effect of CT2 on lipid metabolism. Therefore,
we concentrated our efforts on this CT.
Fig. 2. The activity of the three chemotypes is evolutionary conserved. (a) The SAR structureswere tested in COS7monkey kidney cells andmurineAML12 hepatocytes for an evolutionary
conserved function. 12–19% of the structural variants showed activity across all cell lines. (b) Example of the lipid storage phenotype in COS7 and AML12 cells caused by treatment with
5 μM CT1 (THI-4), CT2 (TPE-5) and CT3 (AU-6) in the presence of 400 μM and 200 μM OA, respectively. Also see Figure S2. Scale bars in panel (b) represent 50 μm.
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Becausewedetermined that free fatty acidswere normally imported
in CT2 treated cells (Fig. 3c,d), we next asked if CT2 slowed down TAG
synthesis or accelerated TAG breakdown. To study breakdownwe treat-
ed pre-OA loaded cells with CT2 (Fig. 4a, d–g). To study synthesis, we
treated the cells with OA and CT2 at the same time (Fig. 4a–c). We ob-
served that CT2 blocked accumulation of lipid in droplets (Fig. 4;
dose-response information for conditions c, e, and g shown in panel
h), but did not reduce lipid storage once prominent LDs were formed,
consistent with a block in TAG synthesis.
We reﬁned this analysis to determine if CT2 only blocks TAG deposi-
tion under circumstances when cells are challenged by high amounts of
exogenous free fatty acids or also at physiological levels. For this pur-
pose, we treated different models of adipocyte differentiation with
CT2 in the absence of OA. Control 3T3-L1 cells (Fig. 5a), human mesen-
chymal stem cells (Figure S5a–c) and human visceral pre-adipocytes
(Fig. 5b) showed prominent lipid stores post differentiation. However,
when the cells were treated with CT2 prior to and throughout differen-
tiation, cells did not show these lipid deposits (Fig. 5a,b and Figure S5a–
c, p-value in Figure S5c = 0.001).
Ectopic fat deposition is a prominent complication of metabolic dis-
orders such as obesity or type 2 diabetes and is highly associated with
insulin resistance (Sattar and Gill, 2014; Shulman, 2014). Thus, we
also explored the response of patient derived cells to CT2 treatment.
Particularly, we tested for the ability of CT2 to block lipid deposition in
differentiated myotubes obtained from a muscle biopsy of a male type
2 diabetes patient. Differentiated myotubes store LDs when they are
provided with OA in the presence of DMSO or an inactive CT2 variant
(Figure S5d). In contrast, whenwe treatedwith active CT2,we observed
strong blockage of lipid deposition (Figure S5d).
The inability to generate lipid deposits following CT2 treatment ap-
pears to be limited to neutral lipid LDs as cholesterylester dropletdeposition was unaffected (Fig. 5c and Figure S6). This is also consistent
with a speciﬁc effect of CT2 on TAG synthesis. We conﬁrmed this hy-
pothesis by lipid proﬁling (by TLC or HPLC coupled to light scattering)
of CT2 treated ﬂy Kc167 or mammalian COS7 cell extracts (Fig. 5d,e;
p-value = 8.32E-6 for TAG, p-value = 0.37 for PC and Figure S6b; p-
value = 3.57E-6 for TAG, p-value = 0.21 for PC). These data indicate
that CT2 speciﬁcally inhibits the formation of TAG-speciﬁc LDs.
While the lipid storage data are consistent with a block in the
conversion of DAG to TAG, we did not observe an increase in DAG
levels in TLC analyses of lipid extracts from cells treated with CT2
in the presence of OA for 16 h (Fig. 5d,e). A possible explanation is
that cells divert DAG when there is no LD available that can serve
as a “sink”. In support of this hypothesis, mice mutant for the DAG
speciﬁc hormone-sensitive lipase accumulate DAG (Haemmerle
et al., 2002). In these mice, lipogenesis is not affected and LDs are
present to store DAG. In contrast, mice mutant for the enzymes
converting DAG to TAG (diaclyglycerol acyltransferases 1 and 2;
DGAT1 and DGAT2) are lean and do not accumulate DAG (Harris
et al., 2011; Liu et al., 2011; Smith et al., 2000; Stone et al., 2004).
To test the hypothesis that DAG accumulation depends on the avail-
ability of a TAG “sink”, we pre-incubated Kc167 cells with OA and
combined the subsequent CT2 treatment with mild lipolytic condi-
tions before we analyzed lipid extracts of these cells by TLC
(Fig. 5f). Intriguingly, this experimental regimen did indeed result
in the accumulation of 1.3-DAG speciﬁcally in combination with
CT2 treatment. Absence of DAG accumulation for the other two CTs
further supports different mechanisms-of-action between CT2 ver-
sus CT1 & 3.
While we focused on the role of CT2 in TAG metabolism, we also
looked for evidence of adverse effects on cell function because excess
OA can be toxic. The inability to store internalized free fatty acids in
TAG was not toxic in our CT treatments (Fig. 1c,d) and did not result
in overt ultrastructural changes to cells as determined by electron
54 K. Tschapalda et al. / EBioMedicine 8 (2016) 49–59microscopy (Fig. 5g). The RNA-Seq experiments demonstrating upregu-
lation of genes encoding beta-oxidation enzymes is consistent with the
increased elimination of excess fatty acids in CT2 treated cells. Indeed,
we directly observed increased fatty acid beta oxidation rates in murine
AML12 cells treated with CT2 in the presence of OA (Fig. 5h, p-value =
1.32E-5 for CO2 production; p-value = 1.25E-4 for amount of ASM).3.5. CT2 Rescues Diet and Genetically Induced Obesity in Whole Flies
Smallmolecules active in a cellular context are not necessarily active
in thewhole organism. Flies can be rapidly tested for small molecule ac-
tivity in physiological conditions. Freshly eclosed sex-separated adult
ﬂies which we placed for six days on CT2 containing food showed a
55K. Tschapalda et al. / EBioMedicine 8 (2016) 49–59modest reduction of TAG levels (Fig. 6a; p-value= 0.015 for female and
0.055 for male ﬂies). More impressively, third instar larvae, which store
copious amounts of lipid to support metamorphosis (Fig. 6b; p-value=
2.96E-5), as well as virgin ﬂies (Fig. 6c; p-value = 1.67E-4 for female
and 4.95E-6 for male ﬂies), that completed their whole development
on small molecule containing food, showed dramatically decreased
TAG storage (reduction to 60% or 33% of the TAG amount of DMSO treat-
ed reference animals for larvae or freshly hatched ﬂies, respectively).
These data indicate that CT2 is bioavailable and effective in whole or-
ganisms. Flies that completed their whole development on CT2 contain-
ing food did not show any signs of toxicity, developmental defects or
developmental delay indicating a general lack of adverse outcomes fol-
lowing CT2 treatment (data not shown).
In order to test whether CT2might also protect from diet-induced or
genetically-induced obesity, we kept small molecule treated ﬂies on a
high-fat diet (HFD) or treated ﬂies deﬁcient for the brummer lipase
(Grönke et al., 2005), the ﬂy homolog of the mammalian adipose tri-
glyceride lipase (ATGL; (Haemmerle et al., 2006)), with CT2. Flies fed
a HFD had signiﬁcantly increased TAG content (Fig. 6d; p-value =
6.04E-3 for female and 4.00E-3 for male ﬂies). Importantly, when ﬂies
on a HFD were treated with CT2, TAG storage amounts were greatly re-
duced and approached the TAG levels of control ﬂies (Fig. 6d; p-value=
1 for female and 0.196 for male ﬂies). In some cases, CT2 ﬂies on a HFD
were even leaner than those on a normal diet.
Obese brummer mutant ﬂies were also more lean following CT2
treatment (Fig. 6e; p-value = 0.002 for female ﬂies). Rescue of the
brummer obesity phenotype is consistentwith the idea that CT2 activity
is independent of increased lipolysis levels as suggested by the tissue
culture experiments shown in Fig. 4. Thus, both dietary and genetically
induced obesity in ﬂies was rescued by CT2 treatment.
3.6. The Activity of CT2 Stems on DGAT1 Inhibition Based on Drosophila
Epistasis Experiments and a Direct Functional Assay
In order to determine if the TAG synthesis pathway was exclusively
affected by CT2 in whole ﬂies, we combined small molecule treatment
with ﬂies carrying mutations resulting in a lean phenotype. Such classi-
cal epistasis experiments have the potential to reveal whether two per-
turbations resulting in the same phenotype act in the same or separate
pathways. In the case where the combined genetic and CT2 perturba-
tions show an additive or synergistic effect, it is likely that the two per-
turbations act in separate pathways. In contrast, if there is no
enhancement of the separate genetic and CT2 perturbations, they pre-
sumably act in the same pathway. As a control, we treated lean PLIN2
mutant ﬂies, whose phenotype is based on a de-protection of LDs
from lipolysis (Grönke et al., 2003)with CT2. As expected, this combina-
tion resulted in a clear additive phenotype that made ﬂies even leaner
(Fig. 6f; p-value= 2.2E-7). This observation strongly suggests indepen-
dence of the genetic and CT2 perturbations. However, when we treated
ﬂies mutant for midway, which encodes the ﬂy homolog of DGAT1
(Buszczak et al., 2002), with CT2 the phenotype was the same as ob-
served with the individual perturbations (Fig. 6f; p-value = 1). Thus
CT2 phenocopiesmidway. This along with the ﬁnding thatmidwaymu-
tant ﬂies are non-responsive to CT2 strongly indicates that CT2 targets
the DGAT1 TAG synthetic pathway. We found no evidence that any as-
pect of the CT2 phenotype is in a non-DGAT1 pathway.Fig. 3. The different CTs provoke diagnostic transcriptional responses and the uptake of fatty aci
CT treatment in the presence or absence of 200 μMOAwith either 1 μMactive (CT1= THI-4, CT
73) compound derivatives. (a) Expression proﬁles showing differentially expressed (DE) gene
scores, are presented in 5 k-means clusters of genes (rows). (b) Drosophila melanogaster sp
responses (see color legend). (c) COS7 cells were kept in medium containing either DMSO, o
the cells were washed and internalized radioactivity was quantiﬁed by scintillation countin
Drosophila S3 cells incubated with the QBT-ﬂuorescent fatty acid uptake reagent (Molecular D
supplemented with DMSO, DMSO and 800 μM OA or 5 μM TPE-5 solved in DMSO. Scale bar re
*p b 0.05; **p b 0.01; ***p b 0.001. Results between two independent groups were determin
http://dx.doi.org/10.1016/j.ebiom.2016.04.014.We have accumulated a great deal of evidence that CT2 targets
DGAT1 with high speciﬁcity. To directly test this hypothesis, we per-
formed functional activity tests in the form of an in vitro esteriﬁcation
assay (Fig. 6g and Supplemental Experimental Procedures section in
the online version at http://dx.doi.org/10.1016/j.ebiom.2016.04.014).
For this purpose, we incubated cell extracts of a yeast quadruplemutant
that is unable to synthesize neutral lipids, or extracts from such quadru-
plemutant cells that expressed themurineDGAT1or DGAT2 enzymeei-
ther of which is sufﬁcient to restore esteriﬁcation activity, with
radiolabeled acyl-CoA and diacylglycerol. Afterwards, we measured
the amount of esteriﬁed triacylglycerol by scintillation counting. Here,
we found a speciﬁc CT2mediated inhibition of theDGAT1enzymeactiv-
ity (Fig. 6g; p-value = 9.30E-6 for DGAT1 and p-value = 0.62 for
DGAT2) with an IC50 of 27 nM (Figure S7a).
4. Discussion
Our phenotypic screen identiﬁed a signiﬁcant number of small mol-
ecules that reduce cellular lipid storage with little to no toxicity and we
explored three of them in greater detail. The quantitative screening
strategy, which results in dose-response information in combination
with the secondary screening for cytotoxicity, provided good conﬁ-
dence with respect to activity. Thus, our dataset represents a valuable
resource to the research community and likely harbors further hit struc-
tures worth investigation.
The RNA-Seq experimentswith smallmolecule treated cellswere able
to reveal diagnostic gene expression proﬁles supporting different
mechanisms-of-action for CTs 1/3 and 2. Indeed, further experiments
such as the small molecule treatment coupled to TLC analysis of lipid ex-
tracts (Fig. 5f) supports different mechanisms. These results further con-
solidate the use of transcriptional proﬁling experiments to characterize
small molecule activities in order to identify potential mechanisms-of-
action for detailed follow-up (Anandhakumar et al., 2015).
Our case-study in small molecule characterization, where direct
screeningwas done in Drosophila cells to easily segue into the facile ge-
netics of the streamlined ﬂy genome, resulted in the identiﬁcation of a
class of inhibitors of the mammalian drug target DGAT1. This enzyme
was previously identiﬁed as a priority drug target, as DGAT1 mutant
mice are viable and show numerous beneﬁcial metabolic characteristics
such as resistance to diet-induced obesity and increased insulin or lep-
tin sensitivity (Smith et al., 2000). In contrast, loss of DGAT2 function
in mice results in severely reduced TAG levels and death shortly after
birth (Harris et al., 2011; Liu et al., 2011; Smith et al., 2000; Stone
et al., 2004). These effects could not be rescued by DGAT1, which sug-
gests fundamentally different roles of the two enzymes in mammalian
lipid metabolism (Stone et al., 2004). DGAT2 variants were also detect-
ed in multiple human GWAS studies, for example associated with HDL-
cholesterol levels (Willer et al., 2013), or N6 polyunsaturated fatty acid
levels (Guan et al., 2014). Interestingly, no human GWAS associations
are described for DGAT1, although a recent report described DGAT1 se-
quence variants associatedwith improved unsaturatedmilk fat concen-
trations in cattle (Lehnert et al., 2015).
Several lead structures for DGAT1 inhibitors have been developed,
some of which entered clinical trials (Birch et al., 2010; Devita and
Pinto, 2013;Matsuda and Tomoda, 2007). The CT2 TPE scaffoldwe iden-
tiﬁed is structurally different from the previously described DGAT1ds is unaffected by CT2.We investigated the transcriptional response of S3 cells after 4 h of
2= TPE-69, or CT3=AU-6) or 1 μM inactive (CT1= THI-68, CT2= TPE-67, or CT3=AU-
s between treated and control samples. The scaled DE gene expression values (FPKM), Z
eciﬁc KEGG metabolic pathways with highlighted reactions involved in small molecule
r 5 μM TPE-5 in DMSO. The cells were subsequently loaded with radiolabeled fatty acids,
g (bars provide mean ± standard deviation (s.d.), n = 3 wells). (d) Confocal images of
evices). On top of the fatty acid uptake reagent, the cell medium was either additionally
presents 10 μm. The following signiﬁcance levels are used: not signiﬁcant (n.s.) p ≥ 0.05;
ed by Student's t-test. Also see Figures S3, S4 and Tables S1–S5 in the online version at
Fig. 4. CT2 does not act via increased lipolysis. (a) Experimental outline of CT2 feeding (all conditions: 5 μM TPE-5) regimens in Drosophila S3 cells and cross-references to the
corresponding images shown in (b–g). (h) Dose-response curves to the conditions shown in (c, e, g). Points represent single well measurements. Lipid droplets are stained with
BODIPY493/503 and Nuclei/DNA with DAPI. Scale bar represents 50 μm.
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CT2 outperformed two previously described DGAT1 inhibitor struc-
tures. Theseﬁndings togetherwith the activity of CT2 in cellular systems
relevant to human physiology, such as the isolated human muscle cells
(Figure S5d) or differentiated human visceral pre-adipocytes (Fig. 5b),
further support useful applications of this CT.
While DGAT1 knockout cells are still capable of lipid deposition in
the course of adipocyte differentiation (Harris et al., 2011), CT2
treatment blocked lipid deposition prominently in different systems
of adipocyte differentiation. One possible explanation for this obser-
vation is that our CT2 structures also affect other cellular targets
which thus results in polypharmacology. At least in ﬂies, however,
epistasis does not support the polypharmacology model (Fig. 6f
and Figure S7d; p-value = 1). An alternative explanation for this dis-
crepancy can be found in the varying expression levels of DGAT en-
zymes in different tissues. However, for Aurora kinases, or
members of the phosphatidylinositol-3-OH kinase (PI(3)K) family
(reviewed e.g. in: (Weiss et al., 2007)), the observed discrepancy be-
tween small molecule based inhibition and the lack-of the target
protein as a result of RNAi or mutation was not based on altered ex-
pression levels of surrogate proteins. In theory, the observed differ-
ences could also be linked to the distinct roles of DGAT1 and
DGAT2, which are not yet elucidated completely. In fact, ample
data support functions that are only partially overlapping. For exam-
ple, while DGAT2 appears to be involved in the majority of TAG syn-
thesis in mice (Stone et al., 2004), DGAT1 knockout mice show
milder phenotypes (Smith et al., 2000). However, altered DGAT1
levels affect the majority of cellular LDs (Wilﬂing et al., 2013). The
latter ﬁnding might indicate that DGAT1 is important for the ﬁrst
steps of LD biogenesis. Our data potentially indicate that there is a
difference between pharmacological inhibition of DGAT1 and ab-
sence of DGAT1 based on mutation. While DGAT1 is inactivated as
a result of the compound activity, its presence could hinder DGAT2
to functionally replace it perhaps based on steric hindrance orpreferential binding of other members of the lipogenic machinery.
Thus, further experiments comparing the small molecule effects to
the true loss-of-function results might help to elucidate the interplay
of DGAT1 and DGAT2.
Impaired esteriﬁcation of free fatty acids and acyl-CoAs due to inac-
tivation of DGAT1 is problematic to cells. Accumulation of thesemetab-
olites has profound consequences on cells ranging from an impact on
cellular signaling (Cai et al., 2011; Takahashi et al., 2006; Wellen et al.,
2009) to the dysfunction and death of the cell caused by lipotoxicity
(Zámbó et al., 2013; Listenberger et al., 2003; Rial et al., 2010). One
way to counteract the accumulation of free fatty acids and acyl-CoAs is
their beta-oxidationmediated breakdown.DGAT1deﬁcientmurinepri-
mary hepatocytes are indeed protected from steatosis by decreased li-
pogenesis and increased beta-oxidation rates (Villanueva et al., 2009).
Similarly, pharmacological inhibition of DGAT1 in enterocytes of rats
enhances intestinal fatty acid oxidation and thus reduces energy intake
(Schober et al., 2013). We also observed an increased expression of
beta-oxidation associated genes (Fig. 3) and the beta-oxidation rate it-
self (Fig. 5h) downstream of CT2 treatment.
Our epistasis experiments highlighted DGAT1 as potential target of
CT2 activity. This is a general advantage of testing small molecules in
ﬂies, as knockout and knockdown mutants are available for almost all
genes. Additionally, most ﬂy genes are conserved in humans, and the
ﬂy genome has not undergone the duplications of genes that occurred
in the vertebrates which simpliﬁes genetics and the evaluation of ex-
pression proﬁles. The ﬂy is thus an excellent pharmacogenomics
model system for tackling the problem of identifying drug targets fol-
lowing high-throughput phenotypic screening. As in our case, most ex-
ploratory screening campaigns are performed using tissue culture cells.
However, cellular systems are limited by the absence of physiological
context for testing efﬁcacy, bioavailability, and toxicology. We see the
ﬂy as a valuable intermediary test step - with the beneﬁt of speed, re-
duced ethics limitations, and a rich genetics toolbox— prior to transfer-
ring candidate small molecules to vertebrate model systems.
Fig. 5. Detailed analysis of the CT2 induced lipid storage phenotype. (a) Murine 3T3-L1 or (b) human visceral pre-adipocytes were differentiated into adipocytes in the presence of 5 μM
CT2 (TPE-5)which results in blocked lipid deposition. DNA is shown in blue (DAPI) and neutral lipids in green (BODIPY 493/503). (c) Drosophila Kc167 cells incubatedwith 1 μg/mLNBD-
cholesterol in the presence of DMSO only, DMSO and 800 μM OA or 5 μM CT2 (TPE-5) solved in DMSO. CT2 does not affect the deposition of cholesterylester droplets. (d) Thin layer
chromatography analysis of lipid extracts of Kc167 cells treated with 5 μM of CT2 (TPE-5). (e) HPLC coupled to light scattering detection analysis of cells treated as in (d). Bars
represent mean ± s.d, n= 3 wells. (f) Kc167 cells were pre-fed with 400 μM OA overnight before the medium was replaced with serum free medium including either DMSO or 5 μM
of CT1 (THI-4), CT2 (TPE-5) or CT3 (AU-6). After 4 h lipids were extracted and analyzed by TLC. (g) Electron micrographs of Drosophila Kc167 cells incubated in the absence or
presence of 800 μM OA and DMSO or 5 μM of CT2 (TPE-5) for 18 h. (h) Murine AML12 hepatocytes were incubated with 5 μm of CT2 (TPE-5) and the rate of beta oxidation was
quantiﬁed based on the CO2 production or the amount of acid soluble metabolites (ASM), respectively. Bars represent mean ± SEM, n = 4 wells. Also see Figures S5 and S6. The
following signiﬁcance levels are used: not signiﬁcant (n.s.) p ≥ 0.05; *p b 0.05; **p b 0.01; ***p b 0.001. Results between two independent groups were determined by Student's t-test.
Scale bars in (a,b) represent 50 μm, in (c) 10 μm and in (g) 5 μm.
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Fig. 6. CT2 shows in vivo activity and is an inhibitor of DGAT1 activity. (a) Freshly eclosed white minus ﬂies were transferred to food containing 10 μM CT2 (TPE-5). After 6 days of
incubation at 18 °C the TAG levels were measured. (b) TAG levels of third instar larvae or (c) adult ﬂies raised on food containing 10 μM CT2 (TPE-5). (d) TAG levels of DMSO or CT2
(TPE-5) treated ﬂies raised on a standard or high-fat diet (HFD; 10% coconut oil) food. Flies were raised on standard food containing either DMSO or 10 μM CT2 (TPE-5), before they
were transferred to standard or HFD food containing either DMSO or 10 μM CT2 (TPE-5). TAG levels were measured with 7 day old ﬂies. (e) TAG levels of adult female ﬂies
heterozygous or homozygous for brummer raised on food containing either DMSO alone or 10 μM CT2 (TPE-5). (f) In vivo epistasis experiments. Lsd-2 homo- or heterozygous and
midway homo- or heterozygous ﬂies were raised on ﬂy food containing either DMSO or 10 μM of CT2 (TPE-5). Subsequently, the TAG content of freshly eclosed male ﬂies was
measured by a colorimetric assay. Colored bar plots in a, c, and d represent data for female (grey) or male (blue) adult ﬂies. Bars in (a–f) represent mean ± s.d., n = at least three
times ﬁve larvae or eight adult ﬂies. See also Figure S7. (g) Diacylglycerol activity assays using 5 μM of TPE-5. Murine DGAT1 or DGAT2 was expressed in quadruple mutant S.cerevisiae
cells (QM) which store no lipid (see Supplemental Experimental Procedures section for details). Bars represent mean ± s.d., n = 3 wells. Multiple comparisons in (d–f) were
determined by one-way ANOVA followed by Bonferroni's post-hoc testing. All other pairwise comparisons were determined by Student's t-test. The following signiﬁcance levels are
used: not signiﬁcant (n.s.) p ≥ 0.05; *p b 0.05; **p b 0.01; ***p b 0.001.
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